{"id":"dwp450","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Hypoglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DWP450 binds to and activates the glucagon-like peptide-1 (GLP-1) receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion. The drug also suppresses glucagon secretion and slows gastric emptying, collectively reducing postprandial and fasting blood glucose levels. Its extended half-life allows for less frequent dosing compared to shorter-acting GLP-1 agonists.","oneSentence":"DWP450 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:28.141Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06354127","phase":"PHASE3","title":"DWP450 for Treating Moderate to Severe Glabellar Lines","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2020-08-12","conditions":"Moderate to Severe Glabellar Lines","enrollment":473},{"nctId":"NCT04294251","phase":"PHASE3","title":"Efficacy and Safety of DWP450 in Subjects With Benign Masseteric Hypertrophy","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2020-03-04","conditions":"Benign Masseteric Hypertrophy","enrollment":180},{"nctId":"NCT02428608","phase":"PHASE2","title":"Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006","status":"COMPLETED","sponsor":"Evolus, Inc.","startDate":"2015-05","conditions":"Glabellar Frown Lines","enrollment":570},{"nctId":"NCT02184988","phase":"PHASE2","title":"Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines","status":"COMPLETED","sponsor":"Evolus, Inc.","startDate":"2014-08","conditions":"Glabellar Frown Lines","enrollment":352},{"nctId":"NCT02334436","phase":"PHASE3","title":"A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002","status":"COMPLETED","sponsor":"Evolus, Inc.","startDate":"2015-01","conditions":"Glabellar Frown Lines","enrollment":324},{"nctId":"NCT02334423","phase":"PHASE3","title":"A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001","status":"COMPLETED","sponsor":"Evolus, Inc.","startDate":"2015-01","conditions":"Glabellar Frown Lines","enrollment":330},{"nctId":"NCT03517319","phase":"PHASE4","title":"Dose-response Relationship of Botullinum Toxin (DWP 450) for Finger Flexor Spasticity","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2016-09-01","conditions":"Spasticity as Sequela of Stroke","enrollment":78},{"nctId":"NCT03369990","phase":"PHASE2","title":"DWP450 Treatment in Subjects With Benign Masseteric Hypertrophy","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2017-12","conditions":"Benign Masseteric Hypertrophy","enrollment":98},{"nctId":"NCT03184363","phase":"PHASE3","title":"Efficacy and Safety of DWP450 for Treating Crows Feet Lines(CFL) in Combination With Glabellar Lines(Extension Study)","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2017-07","conditions":"Crow's Feet Lines, Glabellar Lines","enrollment":102},{"nctId":"NCT02882893","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of DWP450 for the Treatment of Crows Feet Lines","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2016-08","conditions":"Crows Feet Lines","enrollment":238},{"nctId":"NCT01945684","phase":"PHASE3","title":"A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2013-09","conditions":"Spasticity, Stroke","enrollment":197},{"nctId":"NCT01629875","phase":"PHASE3","title":"Efficacy and Safety of DWP450 Compared With Botox in Moderate to Severe Glabellar Line","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2012-03","conditions":"Moderate to Severe Glabellar Line","enrollment":268}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DWP450","genericName":"DWP450","companyName":"Daewoong Pharmaceutical Co. LTD.","companyId":"daewoong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DWP450 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}